Table 1.
Patient and tumor characteristics in the training and test cohort.
| Characteristics | Training cohort | P | Test cohort | P | |||
|---|---|---|---|---|---|---|---|
| Wild-type group (n = 104) | Mutated group (n = 80) | Wild-type group (n = 26) | Mutated group (n = 21) | ||||
| Age | 61.94 ± 12.27 | 64.76 ± 12.96 | 0.133 | 62.12 ± 13.27 | 65.52 ± 12.71 | 0.377 | |
| Gender, n (%) | |||||||
| Male | 57 (54.81%) | 42 (52.50%) | 0.756 | 16 (61.54%) | 10 (47.62%) | 0.340 | |
| Female | 47 (45.19%) | 38 (47.50%) | 10 (38.46%) | 11 (52.38%) | |||
| Tumor location, n (%) | |||||||
| Ascending colon | 30 (28.85%) | 28 (35%) | 0.260 | 2 (7.69%) | 6 (28.57%) | 0.268 | |
| Transverse colon | 6 (5.77%) | 6 (7.5%) | 5 (19.23%) | 4 (19.05%) | |||
| Descending colon | 10 (9.62%) | 4 (5%) | 2 (7.69%) | 2 (9.52%) | |||
| Sigmoid colon | 38 (36.54%) | 20 (50%) | 13 (50%) | 5 (23.81%) | |||
| Rectum | 20 (19.23%) | 22 (27.5%) | 4 (15.38%) | 4 (19.05%) | |||
| Diameter, cm (Mean ± SD) | 5.06 ± 1.85 | 4.78 ± 1.79 | 0.296 | 4.83 ± 1.52 | 5.44 ± 2.70 | 0.359 | |
| Histologic grade, n (%) | |||||||
| Poor | 12 (11.54%) | 11 (13.75%) | 0.621 | 3 (11.54%) | 3 (14.29%) | 0.645 | |
| Moderate | 91 (87.50%) | 69 (86.25%) | 22 (84.62%) | 18 (85.71%) | |||
| Well | 1 (0.96%) | 0 (0.0%) | 1 (3.85%) | 0 (0.0%) | |||
| TNM stage, n (%) | |||||||
| I | 11 (10.58%) | 10 (12.50%) | 0.039* | 3 (11.54%) | 4 (19.05%) | 0.684 | |
| II | 51 (49.04%) | 24 (30%) | 11 (42.31%) | 6 (28.57%) | |||
| III | 33 (31.73%) | 31 (38.75%) | 9 (34.62%) | 7 (33.33%) | |||
| IV | 9 (8.65%) | 15 (18.75%) | 3 (11.54%) | 4 (19.05%) | |||
| T stage, n (%) | |||||||
| T1 | 2 (1.92%) | 1 (1.25%) | 0.909 | 2 (7.69%) | 1 (4.76%) | 0.116 | |
| T2 | 14 (13.46%) | 13 (16.25%) | 2 (7.69%) | 3 (14.29%) | |||
| T3 | 60 (57.69%) | 43 (53.75%) | 17 (65.38%) | 7 (33.33%) | |||
| T4 | 28 (26.92%) | 23 (28.75%) | 5 (19.23%) | 10 (47.62%) | |||
| N stage, n (%) | |||||||
| N0 | 62 (59.62%) | 39 (48.75%) | 0.317 | 14 (53.85%) | 11 (52.38%) | 0.891 | |
| N1 | 26 (25%) | 27 (33.75%) | 6 (23.08%) | 6 (28.57%) | |||
| N2 | 16 (15.38%) | 14 (17.50%) | 6 (23.08%) | 4 (19.05%) | |||
| M stage, n (%) | |||||||
| M0 | 95 (91.35%) | 65 (81.25%) | 0.044* | 23 (88.46%) | 17 (80.95%) | 0.472 | |
| M1 | 9 (8.65%) | 15 (18.75%) | 3 (11.54%) | 4 (19.05%) | |||
| CEA, n (%) ≤ 5 (normal) >5 (abnormal) |
57 (54.81%) 47 (45.19%) |
35 (43.75%) 45 (56.25%) |
0.137 |
16 (61.54%) 10 (38.46%) |
11 (52.38%) 10 (47.62%) |
0.528 |
|
| CA199, n (%) ≤ 39 (normal) >39 (abnormal) |
92 (88.46%) 12 (11.54%) |
63 (78.75%) 17 (21.25%) |
0.073 |
20 (76.92%) 6 (23.08%) |
16 (76.19%) 5 (23.81%) |
0.953 |
|
| CA724, n (%) ≤ 6.9 (normal) >6.9 (abnormal) |
91 (87.50%) 13 (12.50%) |
69 (86.25%) 11 (13.75%) |
0.803 |
23 (88.46%) 3 (11.54%) |
19 (90.48%) 2 (9.52%) |
0.824 |
|
CEA, carcinoembryonic antigen; CA199, carbohydrate antigen-199; CA724, carbohydrate antigen-724. n, number; SD, standard deviation; *P < 0.05.